RENO, Nev., Sept. 19, 2012 /PRNewswire/ -- First Warning
Systems, Inc. announces the availability of its business plan,
slides and supporting documents for the First Warning breast tissue
health technology on the GUST website. The plan details the
need for $5M in capital and the
investment opportunity for qualified investors who participate in
the GUST investor and business plan web site.
The First Warning Business Plan details breakthrough,
paradigm-shift technology to analyze deep tissue cell resistance
changes in the cell microenvironment under the skin.
Microenvironment abnormalities create cell chaos with identifiable
and measurable metabolic phases. 9,600 metabolic phase resistance
data points are captured and converted to thermal values to create
a Dynamic Cell Chaos
Profile.™ Predictive
Analytics Modeling presents an Interpretation of the measurements
giving a clinician a Decision Support protocol without specialized
training or capital equipment investment.
"Qualified investors have an opportunity to participate in the
$11B market for breast health
technology," says Jim Holmes,
Chairman & CEO of First Warning. "Over $13M has been invested in clinical trials, four
patents and the latest Predictive Analytics software technology to
date. Our plans call for completion of the product upgrades,
CU mark and EU market planning to commence commercialization early
in 2013," adds Holmes.
"We are very energized by the prospect of delivering
breakthrough, innovative early detection screening technology that
is effective for women of all ages and tissue types. By using
HIPAA compliant Internet technology, we are able to support
telemedicine delivery models for any type of clinic where our
Decision Support Analytics provide a clinical interpretation
without special training," continues Holmes.
About First Warning Systems Process
Resistance readings of breast tissue abnormalities are measured
with 9,600 data points to create a Dynamic Cell Chaos
Profile™ (9,600 data points) and
correlated to dysfunctional circadian genes. Multiple
bioinformatics algorithms compare the patient Chaos Profile to the
circadian gene profiles to identify breast tissue abnormalities at
different stages of development leading to cancerous cells. FWS
delivers a report to the primary care physician with industry
leading 90% accuracy. The FWS process is the only detection
process that identifies abnormalities before a tumor is large
enough to be measured by current technologies.
About First Warning Systems
First Warning Systems, (FWS) founded in 2008, is based in
Reno, NV. FWS's principal
shareholder is Lifeline Biotechnologies, Inc. (OTC Market: LLBO).
FWS holds the exclusive development, manufacturing and marketing
worldwide license (includes a revenue royalty feature) from
Lifeline, to commercialize the intellectual property. The FWS
product line is a device and process that detects breast tissue
abnormalities leading to health risk assessment and management and
potentially, breast cancer. Three clinical trials with over 650
participants have achieved proof of concept and superior outcomes
when compared to other diagnostic protocols. FWS is planning
a final, limited clinical trial and a 510k device classification to
validate the fourth generation of the FWS product. See
FWS' video, "Breast Cancer Tumor Progression" at
www.firstwarningsystems.com.
Safe Harbor: Statements contained in this release that
are not historical facts may be deemed to be forward-looking
statements. Investors are cautioned that forward-looking
statements are inherently uncertain. Actual performance and
results may differ materially from that projected or suggested
herein due to certain risks and uncertainties including without
limitation, the ability to obtain financing, successful development
of the Company's product or market acceptance of the product and
regulatory and shareholder approval for anticipated
actions.
For more information, contact: Jim Holmes, CEO 775-852-3222
jholmes@firstwarningsystems.com
SOURCE First Warning Systems, Inc.